Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Hs_NS367

ABSTRACT: Hs_NS367

INSTRUMENT(S): LTQ

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Others

SUBMITTER: Steiling et al.

PROVIDER: PAe003793 | PeptideAtlas |

REPOSITORIES: PeptideAtlas

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	PAe003793_7638_tandem.params	Other
	PAe003793_README	Other
	PAe003793_Search_Results_7638_201211210633.properties	Other
	PAe003793_Search_Results_7638_201211210633.tar.gz	Other
	PAe003793_mzML_201211210631.properties	Other

Items per page:

1 - 5 of 8

Similar Datasets

Plasma protein-profiling to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma (LA-NPC)

Project description:Plasma protein expression patterns can be used as prognostic biomarkers in various types of cancer. We aimed to identify a protein-based signature for distant metastatic risk assessment in patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC).

2020-09-02 | GSE149587 | GEO

Role of Sympathic Nervous System and RGM-A in the Resolution of Inflammation

Project description:Protein and phosphorylation (Phospho Explorer Antibody Array, FullMoonBioscience, #PEX100) profiling of peritoneal monocytes (pooled lavages from 3-4 mice / condition) was carried out according to the manufacturer’s instructions.

2018-12-19 | GSE122569 | GEO

Buparlisib-treated Patient Derived Xenograft (PDX) Reversed Phase Protein Array (RPPA) Data

Project description:Phosphoinositide 3-kinase (PI3K) signaling activation is frequently observed in triple negative breast cancer, however, PI3K inhibitors have shown limited clinical activity. To investigate resistance mechanisms, we performed global transcriptome, proteome, phosphoproteome and kinome analysis of a panel of triple negative breast cancer patient derived xenograft models with varying responsiveness to buparlisib, a pan-PI3K inhibitor, for differentially expressed baseline and post-treatment biomarkers. Resistance was associated with incomplete inhibition of PI3K and upregulated MAPK/MEK signaling in response to buparlisib. Outlier phosphoproteome and kinome analyses identified additional candidates in association with buparlisib resistance, including NEK9 and MAP2K4. Knockdown of NEK9 or MAPK2K4 reduced both baseline and feedback MAPK/MEK signaling and enhanced buparlisib efficacy in vitro. Interestingly, we show that a complex ins/del in PIK3CA led to a change in buparlisib response in a NEK9/MAP2K4 dependent manner. In summary, our study indicates a role for NEK9 and MAP2K4 in mediating buparlisib resistance and demonstrates the value of unbiased global analyses in uncovering resistance mechanisms to targeted therapy.

2018-05-29 | GSE100567 | GEO

O-GlcNAc transferase recognizes protein substrates using an asparagine ladder in the TPR superhelix

Project description:Abstract: The essential mammalian enzyme O-GlcNAc Transferase (OGT) is uniquely responsible for transferring N-acetylglucosamine to over a thousand nuclear and cytoplasmic proteins, yet there is no known consensus sequence and it remains unclear how OGT recognizes its substrates. To address this question, we have developed a protein microarray assay that chemoenzymatically labels de novo sites of glycosylation with biotin, allowing us to simultaneously as-sess OGT activity across >6000 human proteins. We used this assay to examine the contribution of a conserved asparagine ladder within the lumen of OGT’s superhelical tetratri-copeptide repeat (TPR) domain to substrate selection. When these residues were mutated, OGT retained full activity against short peptides, but showed low to no activity against most of the OGT substrates on the microarray. O-GlcNAcylation of protein substrates in cell extracts was also greatly attenuated. We conclude that OGT recognizes a majority of its substrates by binding them to the asparagine ladder in the TPR lumen proximal to the catalytic domain. This series contains microarray data both comparing the new chemoenzymatic method to antibody-based detection as well as comparing arrays treated with wild-type OGT, 5N5A mutant OGT, or controls not treated with enzyme. Note: all CTD-stained arrays or control array raw files are contained in GSE107911_RAW.tar

2018-02-26 | GSE107911 | GEO

Elucidating drug mechanistics and resistance in HER2-positive breast cancer cell lines by mathematical modeling

Project description:Advancing precision medicine in the field of cancer is still curbed by the fact that a rational basis to predict treatment outcome is missing. To unravel the mechanism behind targeted drugs (trastuzumab, pertuzumab, erlotinib), mathematical modeling employing ordinary differential equations (ODE) was combined with wet-lab experimentation. Experimentation relied on systematic perturbation experiments to monitor the signaling-response towards drugs in the context of EGF signaling in the HER2+ cell lines SKBR3 and HCC1954.

2016-12-31 | GSE55891 | GEO

Protein expression of women with varying BMI [Custom Antibody Array]

Project description:Protein expression was analyzed by antibody array for differences between women of varying BMI.

2016-11-01 | GSE88781 | GEO

The C10orf10 protein profiling of breast cancer specimens based on a tissue array

Project description:Expression levels of C10orf10 protein were obtained for a series of 100 breast cancer tumor specimens.

2017-02-09 | GSE56985 | GEO

Identification of Novel Auto-antibodies in Type 1 Diabetic Patients using a High-density Protein Microarray

Project description:Type 1 diabetes mellitus (T1DM) results from immune mediated destruction of pancreatic beta cells. However, clinical and immunologic phenotypes of T1DM are variable. Several auto-antibodies including GADA, IA-2A, and ZnT8A, were identified in T1DM, but the prevalence of these auto-antibodies varied for a broad spectrum of T1DM. Here, we systemically profiled auto-antibodies from serum samples of 16 T1DM, 16 type 2 diabetes (T2DM) patients, and 27 healthy controls with normal glucose tolerance (NGT) using protein microarrays containing 9,480 proteins. Among 9,480 different proteins on the array, we identified novel auto-antibody candidates (EEF1A1-AAb and UBE2L3-AAb) by M-test coupled with PLS-DA. These auto-antibodies were highly present in T1DM than controls and detected in 40% of T1DM without GADA. Furthermore, these auto-antibodies might help to differentiate subtype of T1DM when combined with GADA. These novel auto-antibodies provide new diagnostic information of T1DM, as well as new insights into the pathogenesis of T1DM.

2014-07-30 | GSE50866 | GEO

Diagnosis and early detection of CNS-SLE in MRL/lpr mice using peptide microarrays (GPL17600)

Project description:In addition to determining possible diagnostic and predictive peptides of lupus and CNS-lupus, we also used our microarray technology along with the Guitope computer program to determine possible natural protein match to five monoclonal autoantibodies that were created using one of the autoimmune MRL/lpr mouse. Submitter states "We have no processed data to submit. We have no gpr files to submit."

2014-05-08 | GSE57389 | GEO

General Approach for Tetramer Based Identification of Autoantigen Reactive B Cells: Characterization of La and snRNP Reactive B Cells in Autoimmune BXD2 Mice

Project description:This SuperSeries is composed of the SubSeries listed below.

2015-02-28 | GSE65290 | GEO